ArticleLeukemia2022
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
Erratum issuedAbstract readLetter
In one paragraph
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Smoldering multiple myeloma: advances in diagnosis and risk stratification, and evolving therapeutic strategies.International journal of hematology · 2026Review
- Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.British journal of haematology · 2026Review
- Diagnosis, risk stratification and management of smouldering multiple myeloma.Nature reviews. Clinical oncology · 2026Review
- An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies.Clinical and experimental medicine · 2026Review
- Next-Generation Biomarkers in Multiple Myeloma: Advancing Diagnosis, Risk Stratification, and Precision Therapy Beyond Current Guidelines.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring.Blood advances · 2025Article
- Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma.European journal of medical research · 2025Article
- Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM.British journal of haematology · 2025Article
- Evaluating serum free light chain ratio as a biomarker in multiple myeloma.Haematologica · 2025Article
- How to Identify and Manage High-Risk Smoldering Multiple Myeloma.Current oncology reports · 2024Review
- Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma.Blood cancer journal · 2024Article
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.American journal of hematology · 2024Review
- The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.Cancers · 2024Review
- Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.Blood cancer discovery · 2024Article
- Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies.Antibodies (Basel, Switzerland) · 2024Review
- Quantitative risk factor analysis of prior disease condition and socioeconomic status with the multiple myeloma development: nationwide cohort study.Scientific reports · 2024Article
- SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.EClinicalMedicine · 2023Article
- Multiple myeloma with acute light chain cast nephropathy.Blood cancer journal · 2023Review
- Smoldering multiple myeloma current treatment algorithms.Blood cancer journal · 2022Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
16 authors.
Alissa VisramDivision of Hematology, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0002-7201-4642
S Vincent RajkumarDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Prashant KapoorDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4342-364X
Angela DispenzieriDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8780-9512
Martha Q LacyDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Morie A GertzDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Francis K BuadiDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-3214-0203
Suzanne R HaymanDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
David DingliDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7477-3004
Taxiarchis KourelisDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8573-9434
Wilson GonsalvesDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Rahma WarsameDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Eli MuchtarDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2210-2174
Nelson LeungDivision of Nephrology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5651-1411
Robert A KyleDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Shaji K KumarDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA. kumar.shaji@mayo.edu.ORCID http://orcid.org/0000-0001-5392-9284
Funding
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Amylou Constance Dueck · 2015 to 2026
$25.5MPrevalence and Progression of Monoclonal GammopathiesR01CA107476 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2004 to 2018
$4.6MOnset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2012 to 2024
$3.2MNCI NIH HHS P50 CA186781NCI NIH HHS R01 CA107476NCI NIH HHS R01 CA168762
Abstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaSmoldering Multiple MyelomaDisease ProgressionFemaleHumansImmunoglobulin Light ChainsMaleProteinuriaImmunoglobulin Light Chains
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.